knowledge -WSS

knowledge

author：knowledge 2025-09-30 22:05:32 - browse：82551

Kidney transplants are the most common organ transplant procedure in the U.S., with 25,000 taking place in 2022. But for patients who receive new kidneys, the transplant is often followed by severe lifelong challenges, many of which are linked to the immunosuppression drug regimen required after surgery to ensure the body does not reject the new organ. These treatments have side effects and toxicities that impact patients’ long-term health, and even survival, leading to a transplant failure rate of 30-50% at the 10-year mark.

Now a new trial sponsored by Medeor Therapeutics, the results of which were presented Thursday at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting, offers hope that stem cell therapy may help patients discontinue their immunosuppressant regime within a year of the transplant.

“The ability to get a transplant without being on lifelong immunosuppression is kind of a dream in transplant, so I can see why this would generate a lot of excitement,” said Sommer Gentry, a professor of surgery at New York University, who was not involved in the study and was not at the actual presentation, but reviewed the trial’s presentation slides.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Medicare drug price negotiation hasn't dried up venture capital

WSS

In Spain, a hospital brews its own CAR

SEC charges former device maker CEO with $41 million fraud

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

National associations that represent hospice owe an apology

Roche's accidental data boosts hopes for anti

What STAT readers think about the FDA and patient advocacy

focus

knowledge

focus

Cancer drug shortages should be causing more outrage

Why health records don't always know when patients are dead

Hollywood unions extend contract negotiations for actors

How the drug

As demand for Covid shots wanes, Moderna seeks its next success

Roche's accidental data boosts hopes for anti

Supreme Court strikes down use of affirmative action

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

The high cost of giving birth even with insurance

PBMs are inflating the cost of generic drugs. They must be reined in

Wikipedia

Can U.S. cancer drug shortages be fixed?

Prime Medicine, Myeloid Therapeutics clash over genome

Can U.S. cancer drug shortages be fixed?

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

How to keep neuroscience’s past racism from being its future

How to keep neuroscience’s past racism from being its future

focus

hotspot

knowledge

explore